NF1 mutations as biomarker of response to immune checkpoint blockades for lung adenocarcinoma patients

Abstract Little is known about immune checkpoint inhibitors (ICI) response of NF1 -mutated lung adenocarcinomas. 341/4,181 (8.2%) TCGA lung adenocarcinomas samples have a somatic NF1 mutation. NF1 -mutated tumors have higher TMB ( p < 0.0001), higher expression of immune genes (“hot phenotype”) and higher CD8 + T cell ( p = 0.03) and macrophage ( p = 0.02) infiltrations compared to NF1 wild-type tumors. NF1 mutation status appears as a candidate predictive biomarker for ICI response in lung adenocarcinoma patients.